Business NewsPR NewsWire • Superior Results Of The Comparative Study Of The Company's Recombinant Two-Component COVID-19 Vaccine ReCOV As Compared To International Mainstream mRNA Vaccine

Superior Results Of The Comparative Study Of The Company's Recombinant Two-Component COVID-19 Vaccine ReCOV As Compared To International Mainstream mRNA Vaccine

Superior Results Of The Comparative Study Of The Company's Recombinant Two-Component COVID-19 Vaccine ReCOV As Compared To International Mainstream mRNA Vaccine

TAIZHOU, China, Dec. 14, 2022 /PRNewswire/ -- Jiangsu Recbio Technology Co., Ltd. (the "Company", together with its subsidiaries, the "Group") is pleased to announce that positive results were achieved for its sequential booster vaccination Phase II study of the recombinant twocomponent...

View More : https://www.prnewswire.com:443/news-releases/superior-results-of-the-comparative-study-of-the-companys-recombinant-two-c...
Releted News by prnewswire
Fortaco expands vehicle cabin capacity in Holic factory Slovakia
Superior Results Of The Comparative Study Of The Company's Recombinant Two-Component COVID-19 Vaccine ReCOV As Compared To International Mainstream mRNA Vaccine
TECNO Unveils the First Flagship Laptop MEGABOOK S1, Breaking the Boundary with High Performance and Lightest Experience
Kartik Jobanputra - Founder & CEO of UAE-based Splashlight Studios - invited to be a member of the esteemed Forbes Business Council